Clinical Trial

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain lymphomas. Patients will either receive myeloablative conditioning or reduced intensity conditioning regimen prior to the transplant. Patients will be followed for 56 days for safety endpoints and remain in follow-up for one year.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-21
notable Primary completion pushed: 2026-05-31 -> 2026-07-14 2026-07-21
minor Completion pushed: 2027-03-31 -> 2029-05-31 2026-07-21
Trial Details
NCT Number NCT05589896
Lead Sponsor Ossium Health, Inc.
Conditions Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Acute Undifferentiated Leukemia, CLL (Chronic Lymphocytic Leukemia), Chronic Myeloid Leukemia (CML), MDS (Myelodysplastic Syndrome) +3 more
Enrollment 12 participants
Start Date 2024-08-16
Primary Completion 2026-07-14 (estimated)
Study Completion 2029-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-20